Immunogenicity and antigenicity of a recombinant chimeric protein containing epitopes of poliovirus type 1

4Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

To design a vaccine that simultaneously prevents both rotavirus (RV) and poliovirus (PV), a PV type 1 (PV1) chimeric protein using RV VP6 as a vector (VP6F) was constructed, expressed in Escherichia coli expression system and characterized by SDS-PAGE, Western blot, immunofluorescence assay and neutralization test. The results showed that the chimeric protein reacted with anti-VP6F and anti-PV1 antibodies and elicited production of serum antibodies against the chimeric protein in guinea pigs. Antibodies against the chimeric protein neutralized RV Wa and PV1 infection in vitro. The results provided a relevant possibility of developing novel approaches in the rational design of vaccines effective against both RV and PV.

Cite

CITATION STYLE

APA

Pan, X. X., Wang, J., Xia, W. Y., Li, X. F., Yang, L. J., Huang, C., & Chen, Y. D. (2016). Immunogenicity and antigenicity of a recombinant chimeric protein containing epitopes of poliovirus type 1. Acta Virologica, 60(3), 234–241. https://doi.org/10.4149/av_2016_03_234

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free